Previous 10 | Next 10 |
2023-12-22 18:18:15 ET Summary Today, we revisit Bicycle Therapeutics plc, a UK-based clinical stage biotech company focused on developing medicines for underserved diseases. The company has inked two significant collaboration deals with large drug makers in 2023 and continues to ...
Nectin-4 portfolio comprised of BT8009 and BT7480 represents potential opportunity to become leader in treating Nectin-4-driven cancers, starting with metastatic urothelial cancer (mUC) Updated BT8009 clinical data continue to support promising response and differentiated safety profile i...
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that the company will host its first Research and Development (R&D) ...
2023-11-24 10:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-02 09:14:48 ET More on Bicycle Therapeutics Bicycle Therapeutics: Pedaling Through Uncertainty Bicycle Therapeutics gains as FDA expedites path for bladder cancer therapy Seeking Alpha’s Quant Rating on Bicycle Therapeutics Historical earnings ...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
R&D Day on December 14 to provide clinical updates for BT8009, BT5528 and BT7480, and highlight broad capabilities of novel Bicycle ® technology Alignment with FDA on expedited development and design of Phase 2/3 registrational trial for BT8009 in metastatic bladder cancer, t...
Bicycle Therapeutics plc (BCYC) is expected to report $-1.06 for Q3 2023
2023-10-23 14:25:26 ET More on Seattle Genetics Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors Seagen ticks higher as EU approves $43B sale to Pfizer Pfizer likely turned over all documents to FTC for Seagen acquistion - r...
Program intended to facilitate CMC development for selected therapies with expedited clinical development timeframes to help patients get access sooner Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its pro...
News, Short Squeeze, Breakout and More Instantly...
Bicycle Therapeutics plc Company Name:
BCYC Stock Symbol:
NYSE Market:
2024-05-09 10:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...